[1] H. Q. J. Al-Ani, N. N. Al-Hayani, and R. M. Al-Ani, “Efficacy of the Examination of Saliva Sample by Reverse Transcriptase-Polymerase Chain Reaction in Detection of SARS-CoV-2 in Al-Fallujah City, Iraq,” J. Pure Appl. Microbiol. 16(4):2416-2424, 2022.
[2] J. S. Tregoning, K. E. Flight, S. L. Higham, Z. Wang, and B. F. Pierce, “Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape,” Nat. Rev. Immunol., vol. 21, no. 10, pp. 626–636, 2021.
[3] A. G. Hadi, M. Kadhom, E. Yousif, and N. Hairunisa, “In COVID-19 time, how to protect myself and others? a review,” J. biomedika dan Kesehat., vol. 3, no. 3, pp. 153–158, 2020.
[4] M. M. Higdon et al., “A systematic review of coronavirus disease 2019 vaccine efficacy and effectiveness against severe acute respiratory syndrome coronavirus 2 infection and disease,” in Open Forum Infectious Diseases. vol. 9, no. 6, p. ofac138, 2022.
[5] L. R. Baden et al., “Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine,” N. Engl. J. Med., vol. 384, no. 5, pp. 403–416, 2021.
[6] A. Fazlollahi et al., “Cardiac complications following mRNA COVID‐19 vaccines: A systematic review of case reports and case series,” Rev. Med. Virol., vol. 32, no. 4, p. e2318, 2022.
[7] Y. Perez et al., “Myocarditis following coronavirus disease 2019 mRNA vaccine: a case series and incidence rate determination,” Clin. Infect. Dis., vol. 75, no. 1, pp. e749–e754, 2022.
[8] N. S. Hendren, M. H. Drazner, B. Bozkurt, and L. T. Cooper Jr, “Description and proposed management of the acute COVID-19 cardiovascular syndrome,” Circulation, vol. 141, no. 23, pp. 1903–1914, 2020.
[9] B. Bozkurt, I. Kamat, and P. J. Hotez, “Myocarditis with COVID-19 mRNA vaccines,” Circulation, vol. 144, no. 6, pp. 471–484, 2021.
[10] A. Luk et al., “Myocarditis and pericarditis after COVID-19 mRNA vaccination: practical considerations for care providers,” Can. J. Cardiol., vol. 37, no. 10, pp. 1629–1634, 2021.
[11] C. Tschöpe et al., “Myocarditis and inflammatory cardiomyopathy: current evidence and future directions,” Nat. Rev. Cardiol., vol. 18, no. 3, pp. 169–193, 2021.
[12] A. L. P. Caforio et al., “Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases,” Eur. Heart J., vol. 34, no. 33, pp. 2636–2648, 2013.
[13] A. Pollack, A. R. Kontorovich, V. Fuster, and G. W. Dec, “Viral myocarditis—diagnosis, treatment options, and current controversies,” Nat. Rev. Cardiol., vol. 12, no. 11, pp. 670–680, 2015.
[14] M. Olejniczak, M. Schwartz, E. Webber, A. Shaffer, and T. E. Perry, “Viral myocarditis—Incidence, diagnosis and management,” J. Cardiothorac. Vasc. Anesth., vol. 34, no. 6, pp. 1591–1601, 2020.
[15] O. Narovlyanskaya and E. J. Winokur, “Viral myocarditis,” Dimens. Crit. Care Nurs., vol. 39, no. 2, pp. 75–80, 2020.
[16] C. Buttà, L. Zappia, G. Laterra, and M. Roberto, “Diagnostic and prognostic role of electrocardiogram in acute myocarditis: A comprehensive review,” Ann. Noninvasive Electrocardiol., vol. 25, no. 3, p. e12726, 2020.
[17] M. Nassar et al., “Corrigendum to ‘COVID-19 vaccine-induced myocarditis case report with literature review’[Diabetes & Metabolic Syndrome: Clinical Research & Reviews Volume 15, Issue 5, September–October 2021, 102205],” Diabetes Metab. Syndr., vol. 15, no. 5, p. 102277, 2021.
[18] K. B. Lewandrowski, “Special Topics: Cardiac Markers in Myocarditis: Cardiac Transplant Rejection and Conditions Other than Acute Coronary Syndrome,” Clin. Lab. Med., vol. 34, no. 1, pp. 129–135, 2014.
[19] S. C. Smith, J. H. Ladenson, J. W. Mason, and A. S. Jaffe, “Elevations of cardiac troponin I associated with myocarditis: experimental and clinical correlates,” Circulation, vol. 95, no. 1, pp. 163–168, 1997.
[20] W. Dwijanarko, H. Mumpuni, and B. Irawan, “Current diagnosis and management of myocarditis,” ACI (Acta Cardiol. Indones., vol. 2, no. 2, 2016.
[21] T. Lampejo, S. M. Durkin, N. Bhatt, and O. Guttmann, “Acute myocarditis: aetiology, diagnosis and management,” Clin. Med. (Northfield. Il)., vol. 21, no. 5, p. e505, 2021.
[22] J. A. Luetkens et al., “Comparison of original and 2018 Lake Louise criteria for diagnosis of acute myocarditis: results of a validation cohort,” Radiol. Cardiothorac. Imaging, vol. 1, no. 3, p. e190010, 2019.
[23] P. Anand and V. P. Stahel, “The safety of Covid-19 mRNA vaccines: A review,” Patient Saf. Surg., vol. 15, no. 1, pp. 1–9, 2021.
[24] S. Pascolo, “Synthetic messenger RNA-based vaccines: from scorn to hype,” Viruses, vol. 13, no. 2, p. 270, 2021.
[25] J. W. Park, P. N. P. Lagniton, Y. Liu, and R.-H. Xu, “mRNA vaccines for COVID-19: what, why and how,” Int. J. Biol. Sci., vol. 17, no. 6, p. 1446, 2021.
[26] Q. Huang, J. Zeng, and J. Yan, “COVID-19 mRNA vaccines,” J. Genet. Genomics, vol. 48, no. 2, pp. 107–114, 2021.
[27] O. Parés-Badell et al., “Local and systemic adverse reactions to mRNA COVID-19 vaccines comparing two vaccine types and occurrence of previous COVID-19 infection,” Vaccines, vol. 9, no. 12, p. 1463, 2021.
[28] W. Woo et al., “Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID‐19 vaccine,” J. Med. Virol., vol. 94, no. 4, pp. 1566–1580, 2022.
[29] S. A. Mouch et al., “Myocarditis following COVID-19 mRNA vaccination,” Vaccine, vol. 39, no. 29, pp. 3790–3793, 2021.
[30] R. Kornowski and G. Witberg, “Acute myocarditis caused by COVID-19 disease and following COVID-19 vaccination,” Open Hear., vol. 9, no. 1, p. e001957, 2022.
[31] M. E. Oster et al., “Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021,” Jama, vol. 327, no. 4, pp. 331–340, 2022.
[32] S. Hassanzadeh, S. Sadeghi, A. Mirdamadi, and A. Nematollahi, “Myocarditis following AstraZeneca (an adenovirus vector vaccine) COVID‐19 vaccination: A case report,” Clin. Case Reports, vol. 10, no. 4, p. e05744, 2022.
[33] R. R. Ling et al., “Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis,” Lancet Respir. Med. 10(7): 679–688, 2022.
[34] M. Ali et al., “COVID-19 and myocarditis: a review of literature,” Egypt. Hear. J., vol. 74, no. 1, pp. 1–9, 2022.
[35] S. Cushion, V. Arboleda, Y. Hasanain, M. D. Beckler, P. Hardigan, and M. M. Kesselman, “Comorbidities and symptomatology of SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)-related myocarditis and SARS-CoV-2 vaccine-related myocarditis: a review,” Cureus, vol. 14, no. 4, 2022.
[36] A. Simone et al., “Acute myocarditis following COVID-19 mRNA vaccination in adults aged 18 years or older,” JAMA Intern. Med., vol. 181, no. 12, pp. 1668–1670, 2021.
[37] D. Gubernot et al., “US Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines,” Vaccine, vol. 39, no. 28, pp. 3666–3677, 2021.
[38] S. Lane, A. Yeomans, and S. Shakir, “Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature,” BMJ Open, vol. 12, no. 5, p. e059223, 2022.
[39] A. A. Shiravi, A. Ardekani, E. Sheikhbahaei, and K. Heshmat-Ghahdarijani, “Cardiovascular complications of SARS-CoV-2 vaccines: an overview,” Cardiol. Ther. 11(1): 13–21, 2022.
[40] A. Matta et al., “Clinical presentation and outcomes of myocarditis post mRNA vaccination: a meta-analysis and systematic review,” Cureus, vol. 13, no. 11, 2021.
[41] J. Montgomery et al., “Myocarditis following immunization with mRNA COVID-19 vaccines in members of the US military,” JAMA Cardiol., vol. 6, no. 10, pp. 1202–1206, 2021.
[42] M. Fraser et al., “COVID-19-associated myocarditis: an evolving concern in cardiology and beyond,” Biology (Basel)., vol. 11, no. 4, p. 520, 2022.
[43] S. Heymans and L. T. Cooper, “Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms,” Nat. Rev. Cardiol., vol. 19, no. 2, pp. 75–77, 2022.
[44] J. W. Gargano et al., “Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices—United States, June 2021,” Morb. Mortal. Wkly. Rep., vol. 70, no. 27, p. 977, 2021.
[45] J. H. Chen et al., “COVID-19 vaccine-related myocarditis: a descriptive study of 40 case reports,” Cureus, vol. 14, no. 1, 2022.
[46] S. Le Vu et al., “Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines,” Nat. Commun., vol. 13, no. 1, p. 3633, 2022.
[47] T. Licata and A. Clements, “Case Report of COVID-19 mRNA Vaccine-Associated Myocarditis,” WMJ Off. Publ. State Med. Soc. Wisconsin, vol. 121, no. 3, pp. E50–E52, 2022.
[48] S. Choi et al., “Myocarditis-induced sudden death after BNT162b2 mRNA COVID-19 vaccination in Korea: case report focusing on histopathological findings,” J. Korean Med. Sci., vol. 36, no. 40, 2021.
[49] A. K. Verma, K. J. Lavine, and C.-Y. Lin, “Myocarditis after Covid-19 mRNA vaccination,” N. Engl. J. Med., vol. 385, no. 14, pp. 1332–1334, 2021.
[50] V. Kytö, J. Sipilä, and P. Rautava, “The effects of gender and age on occurrence of clinically suspected myocarditis in adulthood,” Heart, vol. 99, no. 22, pp. 1681–1684, 2013.
[51] A. Arola, E. Pikkarainen, J. O. T. Sipilä, J. Pykäri, P. Rautava, and V. Kytö, “Occurrence and features of childhood myocarditis: a nationwide study in Finland,” J. Am. Heart Assoc., vol. 6, no. 11, p. e005306, 2017.
[52] X. Huang, Y. Sun, G. Su, Y. Li, and X. Shuai, “Intravenous immunoglobulin therapy for acute myocarditis in children and adults a meta-analysis,” Int. Heart J., vol. 60, no. 2, pp. 359–365, 2019.
[53] M. Kang, F. Mo, M. Witmans, V. Santiago, and M. A. Tablizo, “Trends in Diagnosing Obstructive Sleep Apnea in Pediatrics,” Children, vol. 9, no. 3, p. 306, 2022.
[54] H. Zhao et al., “Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size,” Biomed. Pharmacother., vol. 133, p. 110825, 2021.
)
